Production (Stage)
Gain Therapeutics, Inc.
GANX
$1.73
-$0.07-3.89%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 12.69M | 12.94M | 13.75M | 13.73M | 13.68M |
| Gross Profit | -12.69M | -12.94M | -13.75M | -13.73M | -13.68M |
| SG&A Expenses | 9.88M | 9.63M | 9.56M | 10.24M | 10.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 20.35M | 20.35M | 21.43M | 21.85M | 21.40M |
| Operating Income | -20.35M | -20.35M | -21.43M | -21.85M | -21.40M |
| Income Before Tax | -20.31M | -19.87M | -21.32M | -21.54M | -21.06M |
| Income Tax Expenses | 617.40K | 536.80K | 46.60K | 57.10K | 82.50K |
| Earnings from Continuing Operations | -20.93 | -20.41 | -21.37 | -21.60 | -21.14 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.93M | -20.41M | -21.37M | -21.60M | -21.14M |
| EBIT | -20.35M | -20.35M | -21.43M | -21.85M | -21.40M |
| EBITDA | -20.31M | -20.32M | -21.39M | -21.82M | -21.37M |
| EPS Basic | -0.89 | -0.95 | -1.13 | -1.33 | -1.53 |
| Normalized Basic EPS | -0.54 | -0.58 | -0.71 | -0.83 | -0.95 |
| EPS Diluted | -0.89 | -0.95 | -1.13 | -1.33 | -1.53 |
| Normalized Diluted EPS | -0.54 | -0.58 | -0.71 | -0.83 | -0.95 |
| Average Basic Shares Outstanding | 102.14M | 91.43M | 78.75M | 64.92M | 58.09M |
| Average Diluted Shares Outstanding | 102.14M | 91.43M | 78.75M | 64.92M | 58.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |